Research Reports | Market Assessment
December 2018

Axial Spondyloarthritis | Disease Landscape and Forecast | G7 | 2018

The treatment of axial spondyloarthritis has been transformed in the last decade by the approval of biologics to treat the disease and the recognition that patients without evidence of radiographic damage can be treated, along with the patients who have definitive ankylosing spondylitis. The result has been a billion-dollar market in the seven major pharmaceutical markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). A new wave of change is slated to come to the market, as drugs with new mechanisms of action are approved and as regulatory authorities clear the way for biologics to treat nr-AxSpA in the major markets

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports